【摘要】 目的观察肾康注射液联合奥美沙坦酯治疗高血压合并痛风性肾病的临床疗效与安全性。方法将2014年1月~2015年10月我院收治的190例高血压合并痛风性肾病患者随机分为2组。对照组(n=95)给予奥美沙坦酯片治疗,每日1次,每次20 mg口服;观察组(n=95)在对照组基础上加用肾康注射液治疗,每日1次,每次100 mL静脉滴注。两组治疗疗程均为4周。观察并记录两组患者治疗前后血压、肾功能及不良反应发生情况。结果观察组总有效率为87.36%,对照组总有效率为69.70%,两组比较差异有统计学意义(χ~2=5.08,P<0.05)。治疗后两组血压、尿素氮、肌酐、24 h尿蛋白及微量尿蛋白均有明显下降,其中观察组下降更显著,与对照组比较差异有统计学意义(P<0.05)。两组间不良反应发生率比较,差异无统计学意义(P>0.05)。结论肾康注射液联合奥美沙坦酯能有效降低高血压合并痛风性肾病患者的血压,并改善其肾脏功能,延缓病情发展,且安全可靠。更多还原

【Abstract】 To observe the efficacy and safety of Shenkang injection combined with olmesartan in the treatment of hypertensive patients complicated with gouty nephropathy. METHODS A total of 190 hypertensive patients complicated with gouty nephropathy in our hospital from January 2014 to October 2015 were randomly assigned to receive Shenkang injection combined with olmesartan or olmesartan alone. The blood pressure and renal function in all patients were observed before and after the treatment.Adverse reactions were observed. RESULTS The total effective rate( 87. 36%) of the treatment group was significantly higher than that of control group( 69.7%)( χ~2= 5. 08,P < 0. 05). After the treatment the indicators of blood pressure、urea nitrogen、creatinine、24hours urinary protein、micro albuminuria of patients in the treatment group were significantly lower than those in the control group( P<0.05). The rate of adverse reactions were similar between two groups( P > 0. 05). CONCLUSION Shenkang injection combined with olmesartan is more effective than olmesartan alone in patients with hypertension complicated with gouty nephropathy.更多还原